Role of Lateral Hypothalamic Orexin (Hypocretin) Neurons in Alcohol Use and Abuse: Recent Advances Leigh C. WalkerSarah Sulaiman Ch’ngAndrew J. Lawrence Neuropharmacology (G Aston-Jones, Section Editor) 31 August 2016 Pages: 241 - 252
New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson’s Disease Michael A. KelbermanElena M. Vazey Neuropharmacology (G Aston-Jones, Section Editor) 28 September 2016 Pages: 253 - 261
Pharmacology of the Bed Nucleus of the Stria Terminalis Christelle GlangetasFrançois Georges Neuropharmacology (G Aston-Jones, Section Editor) 09 November 2016 Pages: 262 - 270
Chelators in Iron and Copper Toxicity Michael K. LawsonMarian ValkoKlaudia Jomová Chemical and Molecular Toxicology (J Bolton, Section Editor) 03 October 2016 Pages: 271 - 280
Therapeutic Potential and Mechanisms of Berberine in Cardiovascular Disease Ming ZhangLinjing FengLi Chen Cardiovascular Pharmacology (J Li, Section Editor) 15 September 2016 Pages: 281 - 292
Metabolomics in Cancer Biomarker Research Xiaoyan WangShaoqiu ChenWei Jia Pharmacometabolomics and Toxicometabolomics (C Chen, Section Editor) 11 November 2016 Pages: 293 - 298
Enzyme/Prodrug Systems for Cancer Gene Therapy Obeid M. MalekshahXuguang ChenArash Hatefi Drug Delivery (A Hatefi, Section Editor) 19 October 2016 Pages: 299 - 308
Challenges in the Delivery of Therapies to Melanoma Brain Metastases Gautham GampaShruthi VaidhyanathanWilliam F. Elmquist Molecular Drug Disposition (M Hu, Section Editor) 09 November 2016 Pages: 309 - 325
Challenges and Opportunities with Predicting In Vivo Phase II Metabolism via Glucuronidation From In Vitro Data Shufan GeYifan TuMing Hu Molecular Drug Disposition (M Hu, Section Editor) 08 November 2016 Pages: 326 - 338
The Role of Interaction Model in Simulation of Drug Interactions and QT Prolongation Barbara WiśniowskaSebastian Polak Pharmacometrics (H Kimko, Section Editor) Open access 27 October 2016 Pages: 339 - 344